Core Diagnostics to collaborate with US-based Star Health for oncology test

Core Diagnostics, the clinical diagnostics laboratory, will collaborate with Star Health Network Inc, a New York-based healthcare company, to bring the Celsee Diagnostics’ liquid biopsy test in India. Core Diagnostics will add the CTC (circulating tumour cells) test to its expanding list of tests, and market the product to the patient population across India. 

Technology of Celsee Diagnostics, a privately held Michigan-based company that has developed automated systems to detect CTCs from blood, allows healthcare professionals to determine prognosis of cancer patients and efficacy of drug treatment.

Primary and metastatic tumours shed cells into the bloodstream. These are called circulating tumour cells. The Celsee CTC test detects cancer cells in the blood stream and determines whether cancer treatment is working, or the disease is spreading. The test is a valuable aid to oncologists in evaluating prognosis of metastatic breast, colorectal, prostate and lung cancers.

“We are happy to partner with Star Health Network, and to add this state-of-the-art CTC test to our growing menu. Oncology is a rapidly developing field with a focus on research and early detection. We sincerely hope that this diagnostic test will help oncologists plan the best possible targeted treatments, for the most successful patient outcomes,” said Zoya Brar, founder & managing director, Core Diagnostics.

Dr Jamal Naiyer, CEO of Star Health Network, added, “CTC is an instrumental technology in aiding cancer treatment. Star Health Network is helping commercialise Celsee CTC technology across India and is excited to forge the collaboration with Core Diagnostics.” 

Core Diagnostics Pvt Ltd is a clinical diagnostic laboratory specialising in high-end esoteric tests in the spheres of oncology, reproductive health, cardiology, and endocrinology.